Autoimmune diabetes

Curing, preventing, and reversing autoimmune diabetes  (TIDM) with Tellurium Compounds: Ammonium trichloro(dioxoethylene-o,o’)tellurate (AS101), an immunomodulator, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 4/November/2019, 12.10 pm
Curing, preventing, and reversing autoimmune diabetes  (TIDM) with Tellurium Compounds: Ammonium trichloro(dioxoethylene-o,o’)tellurate (AS101), an immunomodulator, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 4/November/2019, 12.10 pm 1280 720

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Molecular mechanistic insights into how Teplizumab delays the development of autoimmune diabetes  (TIDM):  Teplizumab (also known as PRV-031/MGA031/hOKT3γ1), a humanized anti-CD3 monoclonal antibody,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and delays development of  type I diabetes (TIDM), via up-regulation of its target gene, 1/November/2019, 12.20 pm
Molecular mechanistic insights into how Teplizumab delays the development of autoimmune diabetes  (TIDM):  Teplizumab (also known as PRV-031/MGA031/hOKT3γ1), a humanized anti-CD3 monoclonal antibody,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and delays development of  type I diabetes (TIDM), via up-regulation of its target gene, 1/November/2019, 12.20 pm 1280 720

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Combinatorial therapy for autoimmune diabetes  (TIDM):   A pharmaceutical mixture encompassing Dulaglutide (trade name: Trulicity), a Glucagon-like peptide-1  (GLP-1) receptor agonist, and Verapamil (brand name: Calanm, Isoptin and others), an anti-hypertensive drug,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 23/August/2019, 11.38 pm
Combinatorial therapy for autoimmune diabetes  (TIDM):   A pharmaceutical mixture encompassing Dulaglutide (trade name: Trulicity), a Glucagon-like peptide-1  (GLP-1) receptor agonist, and Verapamil (brand name: Calanm, Isoptin and others), an anti-hypertensive drug,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 23/August/2019, 11.38 pm 1280 720

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Natural product-based curative therapy for autoimmune diabetes  (TIDM):  Repurposing the anti-malarial drug Artesunate into an anti-diabetic drug:  Artesunate, a derivative of Artimesinin, which aids in the treatment of malaria, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/August/2019, 10.09 pm
Natural product-based curative therapy for autoimmune diabetes  (TIDM):  Repurposing the anti-malarial drug Artesunate into an anti-diabetic drug:  Artesunate, a derivative of Artimesinin, which aids in the treatment of malaria, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/August/2019, 10.09 pm 1280 720

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Curing autoimmune diabetes  (TIDM) with HDAC (Histone deacetylase) inhibitors: Givinostat/Gavinostat-based therapy for autoimmune diabetes:Givinostat/Gavinostat, a histone deacetylase inhibitor used to treat systemic juvenile idiopathic arthritis,polycythaemia vera., Duchenne muscular dystrophy and others, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 5/July/2019, 11.19 pm
Curing autoimmune diabetes  (TIDM) with HDAC (Histone deacetylase) inhibitors: Givinostat/Gavinostat-based therapy for autoimmune diabetes:Givinostat/Gavinostat, a histone deacetylase inhibitor used to treat systemic juvenile idiopathic arthritis,polycythaemia vera., Duchenne muscular dystrophy and others, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 5/July/2019, 11.19 pm 1280 720

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Curing autoimmune diabetes  (TIDM) with interleukin 1 receptor antagonists:Anakinra-based therapy for autoimmune diabetes: Anakinra (brand name: Kineret and others),  an interleukin 1 receptor antagonist used in the treatment of rheumatoid arthritis, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 4/July/2019, 11.03 pm
Curing autoimmune diabetes  (TIDM) with interleukin 1 receptor antagonists:Anakinra-based therapy for autoimmune diabetes: Anakinra (brand name: Kineret and others),  an interleukin 1 receptor antagonist used in the treatment of rheumatoid arthritis, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 4/July/2019, 11.03 pm 1280 720

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more
Start Typing